Nucleic acid delivery vector, nucleic acid delivery vector set, nucleic acid delivery composition, and nucleic acid delivery method

By using nucleic acid delivery vectors containing donor DNA, RNA agents, and lipid particles, the problem of functional proteins being difficult to integrate into the genome within cells has been solved, enabling efficient genetic engineering applications.

CN118979066APending Publication Date: 2024-11-19KK TOSHIBA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411097059.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-07-23
Filing Date
2020-02-28
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing technologies have difficulty effectively introducing functional proteins such as CRISPR-associated protein 9 (CAS9) and transposases into cells and integrating them into the genome, resulting in low efficiency in genetic engineering.

Method used

The nucleic acid delivery vector contains donor DNA, an RNA agent encoding a protein, and lipid particles that encapsulate the donor DNA and RNA agent. It utilizes a combination of nucleic acid condensation peptides and specific lipids to improve the encapsulation efficiency and intracellular delivery efficiency of nucleic acids.

Benefits of technology

It improves the intracellular delivery efficiency and gene integration efficiency of functional proteins, enhances the effect of genetic engineering, and is applicable to gene therapy, genome diagnostics and other fields.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979066A_ABST
    Figure CN118979066A_ABST
Patent Text Reader

Abstract

According to one embodiment, a nucleic acid delivery vector according to one embodiment is used for integrating a first sequence into a cell genome. The nucleic acid delivery vector comprises donor DNA containing a first sequence, an RNA agent containing at least RNA encoding a protein involving integrating the first sequence into a genome, and lipid particles encapsulating the donor DNA and the RNA agent.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application 202080004819.9 of the same name filed on February 28, 2020.

[0002] [Cross-reference to related applications]

[0003] This application is based upon and claims the benefit of priority from Japanese patent application No. 2019-135474, filed on Jul. 23, 2019, the entire contents of which are incorporated herein by reference. [Technical field]

[0004]

[00136] Embodiments described herein generally relate to nucleic acid delivery vectors, sets of nucleic acid delivery vectors, nucleic acid delivery compositions, and nucleic acid delivery methods. [Background technology]

[0005] Recently, many functional proteins that can be used for genetic engineering have been discovered, including CRISPR-associated protein 9 (CAS9) that specifically cuts DNA and transposases that cut out target DNA and insert it into the cell genome. In order to utilize such functional proteins in genetic engineering, a technology has been sought that can introduce and express functional proteins into cells in a more efficient manner.

[0006] For example, a method has been used, which includes delivering a DNA (e.g., a vector) encoding a functional protein into a cell to express the functional protein in the cell. Unfortunately, independent DNA is difficult to penetrate the plasma membrane into the cell. Examples of methods for DNA introduction into cells include the use of liposomes. Liposomes can be combined with nucleic acids to form a complex, making it easy for nucleic acids to be introduced into cells.

Brief Description of the Figures

[0008] Figure 1 is a cross-sectional view showing an example of a nucleic acid delivery vector according to one embodiment.

[0009] Figure 2 is a flowchart showing an example of a nucleic acid delivery method according to one embodiment.

[0010] Figure 3 is a cross-sectional view showing an example of a nucleic acid delivery vector according to one embodiment.

[0011] Figure 4 is a cross-sectional view showing an example of a nucleic acid delivery vector set according to one embodiment.

[0012] Figure 5 It is a graph showing the experimental results of Example 1.

[0013] Figure 6 This is a microscope photograph showing the experimental results of Example 1.

[0014] Figure 7 is a histogram showing the experimental results of Example 2.

[0015] Figure 8 is a histogram showing the experimental results of Example 3.

[0016] Fig. 9 It is a graph showing the experimental results of Example 4.

[0017] Fig.10 is a histogram showing the experimental results of Example 4.

[0018] Fig.11 This is a graph showing the experimental results of Example 5.

[0019] Fig.12 This is an electrophoresis photograph showing the experimental results of Example 6.

[0020] Fig.13 This is a microscope photograph showing the experimental results of Example 6. [Detailed description of the invention]

[0022] Generally, according to one embodiment, the nucleic acid delivery vector according to the embodiment is used to integrate the first sequence into the cell genome. The nucleic acid delivery vector comprises: a donor DNA containing the first sequence; an RNA agent containing at least an RNA encoding a protein, the protein being involved in integrating the first sequence into the genome; and lipid particles encapsulating the donor DNA and the RNA agent.

[0023] Each embodiment will be described below with reference to the accompanying drawings. Each figure is an embodiment and a schematic diagram for promoting its understanding. In addition, the accompanying drawings have sites that are different from the actual form, size and proportion. If appropriate, these designs can be modified, taking into account the following description and known technology.

[0024] According to an embodiment, the nucleic acid delivery vector comprises: a donor DNA containing the first sequence, at least an RNA agent encoding a protein, the protein involving the integration of the first sequence into the genome, and lipid particles encapsulating the donor DNA and RNA agent. The nucleic acid delivery vector is used to integrate the first sequence into the cell genome (i.e., the first sequence is introduced into the cell). In addition, the embodiment provides: a nucleic acid delivery vector group, which comprises a separate lipid particle, each lipid particle encapsulating a donor DNA or RNA agent; a nucleic acid delivery composition, which comprises a nucleic acid delivery vector or a nucleic acid delivery vector group; and a nucleic acid delivery method using a nucleic acid delivery vector or a nucleic acid delivery vector group. Nucleic acid delivery vectors, nucleic acid delivery vector groups, nucleic acid delivery compositions and nucleic acid delivery methods are described in detail below.

[0025] (First embodiment)

[0026]

Nucleic acid delivery vector

[0027] Figure 1 : is a cross-sectional view showing an example of a nucleic acid delivery vector of the first embodiment. The nucleic acid delivery vector 1 comprises a donor DNA 2, an RNA agent 3, and a lipid particle 4 encapsulating the donor DNA 2 and the RNA agent 3. The donor DNA 2 comprises a first sequence 5, which is to be integrated into the cell genome. The RNA agent 3 comprises RNA 3a and a guide RNA 3b. RNA 3a is an RNA encoding a protein, which is involved in integrating the first sequence 5 into the genome. Guide RNA 3b is an RNA containing a sequence corresponding to a sequence on the genomic sequence into which the first sequence 5 is integrated (hereinafter referred to as "the second sequence"). The donor DNA 2 and the RNA agent 3 are encapsulated in a state of being condensed using, for example, a nucleic acid condensing peptide 6. The lipid particle 4 comprises a lipid membrane produced by non-covalently arranged multi-lipid molecules 4a. The lipid particle 4 is an approximately spherical hollow body, which encapsulates the donor DNA 2 and the RNA agent 3 in its central cavity 4b.

[0028] Hereinafter, each configuration will be described in detail.

[0029] The donor DNA 2 is, for example, double-stranded linear DNA. The donor DNA 2 may be single-stranded DNA or circular DNA. The length of the donor DNA 2 is, for example, 3 to about 20,000 nucleotides.

[0030] The first sequence 5 contained in the donor DNA 2 is a sequence to be integrated into the cell genome, and embodiments include: a gene expression cassette containing a promoter sequence, a specific gene and a terminator sequence; a nucleotide sequence encoding a specific gene or a portion of a gene; or a naturally occurring nucleotide sequence or a non-natural nucleotide sequence that is not a gene. The first sequence 5 can be a nucleotide sequence encoding 1 to several amino acids or a sequence consisting of 3 to dozens of nucleotides. The length of the first sequence 5 is, for example, 3 to about 20,000 nucleotides.

[0031] For example, the donor DNA 2 may contain other sequences in addition to the first sequence 5. Such a sequence may be a recognition sequence of a protein encoded by RNA 3a or a recognition sequence of guide RNA 3b.

[0032] The structure of the donor DNA 2 will be described in detail later. That is, the type of the first sequence 5, the type of the additional sequence, the nucleotide length, etc. are selected according to the usage of the nucleic acid delivery vector 1.

[0033] Preferably, the nucleic acid delivery vector 1 contains 1 to 100 molecules of the donor DNA 2 .

[0034] RNA 3a is an RNA encoding a protein involved in the integration of sequence 5 1 into the genome. The protein has the activity of DNA cutting, joining, insertion and / or repair, and is an enzyme that integrates the DNA sequence into the genome by using these activities. Hereinafter, this protein is also referred to as "enzyme". Examples of preferred enzymes include: enzymes with endonuclease activity; transposases; reverse transcriptases and integrases (enzymes for retroviral retrotransposons); reverse transcriptases and endonucleases (enzymes for non-retroviral retrotransposons), etc.

[0035] Examples of enzymes with endonuclease activity include: CRISPR-Assosiated Protein 9 (Cas9), zinc finger nuclease (ZFN), transcription activation effector nuclease (TALEN) or meganuclease, etc. As described in detail later, each endonuclease is involved in integrating the first sequence 5 into the genome by cleaving the phosphodiester bond at the position where the first sequence 5 is integrated into the genome.

[0036] Examples of transposases include: PiggyBac, SleepingBeauty, Frog Prince, Hsma, Minos, Tol1, Tol2, Passport, hAT, Ac / Ds, PIF, Harbinger, Harbinger3-DR, Himar1, Hermes, Tc3, or Mos1, etc. Each transposase has an activity of excising a sequence containing the first sequence 5 from the donor DNA 2 and integrating it into the genome, and thus involves integrating the first sequence 5 into the genome.

[0037] RNA 3a can be, for example, the mRNA of a gene encoding any of the above enzymes. RNA 3a can have additional sequences other than the sequence encoding the enzyme gene. Examples of additional sequences include a 5'-terminal leader sequence, an IRES (internal ribosome entry site), a terminator sequence or a poly (A) sequence. RNA 3a can be terminated.

[0038] The length of RNA 3a is, for example, about 20 to about 5000 nucleotides. Preferably, 1 to about 1000 RNA 3a molecules are contained in the nucleic acid delivery vector 1. RNA 3a may contain a plurality of RNAs encoding different types of enzymes.

[0039] Guide RNA 3b is an RNA having a nucleotide sequence corresponding to the second sequence or its complementary sequence. The second sequence is, for example, a 15-25-mer sequence at or near the position where the first sequence 5 is introduced into the cell genome. The second sequence is DNA, and guide RNA 3b is RNA. Therefore, the "corresponding nucleotide sequence" refers to a nucleotide sequence or its complementary sequence that is identical except that T (thymine) of the second sequence is U (uridine) in guide RNA 3b.

[0040] When RNA 3a is an RNA encoding Cas9, guide RNA 3b is preferably used. At this time, guide RNA 3b can be a guide RNA designed in the CRISPR-CAS9 system based on the second sequence according to the common knowledge of those skilled in the art. In this case, guide RNA 3b can be an RNA containing a 3' end side crRNA of a PAM sequence connected to the 3' end of the second sequence, or a sequence containing a 3' end crRNA containing a PAM sequence and a part of TracrRNA connected to the 3' end of the second sequence (sgRNA). The length of this guide RNA 3b is, for example, about 40 to about 150 nucleotides.

[0041] Guide RNA 3b forms a complex with the endonuclease expressed from RNA 3a, and plays a role in guiding the endonuclease to sequence 2. Therefore, the use of guide RNA 3b allows site-specific integration of sequence 1 5. When site-specific integration of sequence 1 5 is not required or CAS9 is not used as an enzyme, guide RNA 3b does not have to be used.

[0042] Preferably, the nucleic acid delivery vector 1 contains 1 to about 1000 molecules of the guide RNA 3b.

[0043] RNA agent 3 may include additional RNA. Examples of additional RNA include RNA with DNA modification functions, such as DNA methylation, demethylation, repair and / or conjugation. For example, each of these RNAs is an RNA encoding a protein with the above-mentioned modification activity. The inclusion of such RNA makes it possible to add modifications to the first sequence 5 that has been integrated into the genome and its surrounding sequences. Therefore, for example, cells can be further functionally modified.

[0044] Preferably, the RNA included in the RNA agent 3 can be modified to be resistant to degradation. For example, the modification can be a modification known in the art that makes the RNA not degraded by intracellular or extracellular RNases. For example, such a modification involves using / introducing naturally occurring modified nucleotides or non-natural nucleotides in RNA, using / appending non-natural sequences, or adding naturally occurring / non-natural cap structures.

[0045] Examples of naturally occurring modified nucleotides include: pseudouridine, 5-methylcytidine, 1-methyladenosine, etc. Examples of non-natural nucleotides include BNA (bridged nucleic acid), LNA (locked nucleic acid), PNA (peptide nucleic acid), etc.

[0046] The example of non-natural sequence includes artificially synthesized non-natural nucleotide sequence, such as random nucleotide sequence or the crossover sequence of natural / non-natural amino acid and nucleic acid.Preferably, non-natural sequence is added to the end of RNA, for example.

[0047] Examples of naturally occurring cap structures include CAP0 (m7GpppN), CAP1 (m7GpppNm), etc. Examples of non-natural cap structures include ARCA (Anti-Reverse Cap Analog) or LNA-guanosine, etc. Preferably, the non-natural cap structure is added to, for example, the 5' end of the RNA.

[0048] The use of modified RNA as described above can prevent RNA from being degraded by RNases present inside or outside the cell, which may lead to an increase in the integration efficiency of sequence 1 5.

[0049] The nucleic acid condensing peptide 6 is used to condense a large number of nucleic acids into small bodies to effectively encapsulate the nucleic acids in the lipid particles 4. For example, a cationic peptide is preferably used as such a peptide. The cationic peptide can enter the helical gap of, for example, anionic nucleic acids and shorten the gap to condense the nucleic acids.

[0050] Preferred nucleic acid condensation peptides 6 are peptides containing cationic amino acids, for example, in an amount of 45% or more relative to the total amount. More preferred nucleic acid condensation peptides 6 have RRRRRR (the first amino acid sequence) at one end and a sequence RQRQR (the second amino acid sequence) at the other end. In addition, 0 or more intermediate sequences consisting of RRRRRR or RQRQR are included between the above two amino acid sequences. In addition, 2 or more neutral amino acids are included between any two adjacent sequences of the first amino acid sequence, the second amino acid sequence and the intermediate sequence. Examples of neutral amino acids include G or Y.

[0051] The nucleic acid condensation peptide 6 preferably has the following amino acid sequence:

[0052] RQRQRYYRQRQRGGRRRRRR (SEQ ID NO: 1); or

[0053] RQRQRGGRRRRRR (SEQ ID NO: 2).

[0054] Due to the cationicity of R, this nucleic acid condensing peptide can effectively cause the condensation of nucleic acids and weaken the anionic nature of nucleic acids, thereby more effectively encapsulating nucleic acids in lipid particles 4. In addition, this nucleic acid condensing peptide can effectively dissociate nucleic acids in cells, so that the nucleic acids introduced into cells can be effectively expressed in cells.

[0055] Alternatively, the nucleic acid condensation peptide 6 has RRRRRR (the third amino acid sequence) at one end and RRRRRR (the fourth amino acid sequence) at the other end. In addition, 0 or more intermediate sequences consisting of RRRRRR or RQRQR are included between the above two amino acid sequences. In addition, 2 or more neutral amino acids are included between any two adjacent sequences of the third amino acid sequence, the fourth amino acid sequence and the intermediate sequence. Examples of neutral amino acids include G or Y.

[0056] This nucleic acid condensation peptide 6 preferably has the following amino acid sequence:

[0057] RRRRRRYYRQRQRGGRRRRRR (SEQ ID NO: 3).

[0058] This nucleic acid condensing peptide 6 has strong cationic properties at both ends, so it can effectively bind nucleic acids. Therefore, nucleic acids can be condensed more effectively, so that more nucleic acids can be encapsulated in lipid particles 4. This reduces the level of nucleic acids remaining outside the lipid particles 4, thereby preventing aggregation between nucleic acid delivery vectors. Therefore, each nucleic acid delivery vector may be incorporated into cells.

[0059] In addition, the nucleic acid condensing peptide 6 having the following amino acid sequence can be used in combination with any of the above nucleic acid condensing peptides:

[0060] GNQSSNFGPM KGGNFGGRSS GPYGGGGQYF AKPRNQGGY(M9) (SEQ ID NO: 4).

[0061] The peptide can further condense the aggregated nucleic acid 6 condensed by the above-mentioned nucleic acid condensation peptide. Therefore, a smaller-sized nucleic acid delivery vector can be obtained. This nucleic acid delivery vector is easily incorporated into cells, making the integration of nucleic acid into the cell genome more effective.

[0062] For example, before encapsulation in lipid particles 4, donor DNA 2 and RNA agent 3 are condensed by stirring and mixing donor DNA 2 and RNA agent 3 with nucleic acid condensing peptide 6. Donor DNA 2 and RNA agent 3 may be condensed together or separately.

[0063] Since the above-mentioned effects are exhibited, it is preferable to use the nucleic acid condensing peptide 6. However, the nucleic acid condensing peptide 6 may not necessarily be used depending on the types of the donor DNA 2 and RNA agent 3 used, or the types of cells used.

[0064] The lipid particle 4 can be made of a lipid monolayer or a lipid bilayer. In addition, the lipid particle 4 can be made of a monolayer membrane or a multilayer membrane.

[0065] As the material of the lipid particles 4, for example, lipids that are the main components of biological membranes can be used. Examples of such lipids include diacylphosphatidylcholine, diacylphosphatidylethanolamine, ceramide, sphingomyelin, dihydrosphingomyelin, cephalin and cerebrosides. The case of using diacylphosphatidylcholine and diacylphosphatidylethanolamine is preferred because the structure and particle size of the lipid particles 4 are easy to control and can impart membrane fusion energy. The length of the hydrocarbon chain of the acyl group contained in the lipid is preferably C10 to C20. The hydrocarbon chain may be a saturated hydrocarbon group or an unsaturated hydrocarbon group.

[0066] Examples of lipids that can be preferably used include:

[0067] 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),

[0068] 1,2-stearoyl-sn-glycero-3-phosphoethanolamine (DSPE),

[0069] 1,2-Dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC),

[0070] 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylcholine (POPC),

[0071] 1,2-Di-O-octadecyl-3-trimethylammonium propane (DOTMA),

[0072] 1,2-Dioleoyl-3-dimethylammonium propane (DODAP),

[0073] 1,2-Dimyristoyl-3-dimethylammonium propane (14:0DAP),

[0074] 1,2-Dipalmitoyl-3-dimethylammonium propane (16:0DAP),

[0075] 1,2-Distearoyl-3-dimethylammonium propane (18:0DAP),

[0076] N-(4-carboxybenzyl)-N,N-dimethyl-2,3-bis(oleoyloxy)propane (DOBAQ),

[0077] 1,2-Dioleoyl-3-trimethylammonium propane (DOTAP),

[0078] 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC),

[0079] 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),

[0080] 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS), or

[0081] Cholesterol.

[0082] They have the function of forming lipid particles 4 and, when the nucleic acid delivery vector is delivered into cells, have the effect of plasma membrane fusion and / or endocytosis.

[0083] The lipid particles 4 may be composed of a single lipid, but are preferably a lipid mixture containing a plurality of lipids. The type of lipid used in the lipid particles 4 is appropriately selected in consideration of the size of the target lipid particles 4, the type of encapsulated material, the stability in the introduced cells, and the like.

[0084] In addition to the above-mentioned lipids, the lipid particles 4 preferably include a first biodegradable lipid compound. The first biodegradable lipid compound can be represented by the following formula:

[0085] Q-CHR2

[0086] in

[0087] Q is an oxygen-free nitrogen-containing aliphatic group containing 2 or more tertiary nitrogen atoms,

[0088] R is each independently a C12-C24 aliphatic group, and

[0089] At least one R contains a linker LR selected from -C(=O)-O-, -OC(=O)-, -OC(=O)-O-, -SC(=O)-, -C(=O)-S-, -C(=O)-NH-, and -NHC(=O)- in its main chain or side chain.

[0090] When the lipid particle 4 contains the first biodegradable lipid compound, the surface of the lipid particle 4 is non-cationic. Therefore, the difficulty of cell introduction is reduced, thereby increasing the efficiency of nucleic acid delivery. As a result, the first sequence 5 can be effectively integrated into the cell genome.

[0091] As the first biodegradable lipid compound, for example, a lipid having a structure represented by the following formula is preferably used, since the nucleic acid encapsulation amount and nucleic acid delivery efficiency are better.

[0092]

[0093]

[0094]

[0095]

[0096] In addition, the lipid particle 4 preferably further comprises, for example, a second biodegradable lipid compound. The second biodegradable lipid compound can be represented by the formula:

[0097] P-[XWY-W'-Z]2

[0098] in

[0099] P is an alkyleneoxy group containing at least one ether bond in the main chain,

[0100] X is each independently a divalent linking group containing a tertiary amine structure,

[0101] W is each independently a C1-C6 alkylene group,

[0102] Y is each independently a divalent linking group selected from a single bond, an ether bond, a carboxylate bond, a thiocarboxylate bond, a thioester bond, an amide bond, a urethane bond, and a urea bond,

[0103] W' is each independently a single bond or a C1-C6 alkylene group,

[0104] Z's are each independently a fat-soluble vitamin residue, a sterol residue or a C12-C22 aliphatic hydrocarbon group.

[0105] When the second biodegradable lipid compound is included, since hydrogen bonds can be formed between oxygen atoms constituting the ether bonds contained in P and the encapsulated nucleic acid, the encapsulated amount of nucleic acid and the like can be increased.

[0106] The second biodegradable lipid compound having the following structure is preferably used due to better nucleic acid encapsulation amount and nucleic acid delivery efficiency.

[0107]

[0108]

[0109]

[0110] In the case of using lipid particles 4 comprising the above-mentioned first and second biodegradable lipid compounds, the nucleic acid delivery efficiency is improved, and cell death of transfected cells can be reduced. In the case of containing both the first biodegradable lipid compound and the second biodegradable lipid compound, it is easy to apply to gene therapy, nucleic acid medicine, genome diagnosis, etc. It is particularly preferred to use a compound represented by formula (1-01) or formula (1-02) and a compound represented by formula (2-01) because of particularly excellent nucleic acid encapsulation amount and nucleic acid delivery efficiency.

[0111] The lipid particles 4 may also contain additional lipids. Such additional lipids may be optionally selected from those commonly used in lipid particles. Examples of additional substances include, for example, polyethylene glycol (PEG) modified lipids, particularly polyethylene glycol (PEG) dimyristoylglycerol (DMG-PEG), polyamide oligomers derived from ω-amino (oligoethylene glycol) alkanoic acid monomers (U.S. Patent No. 6,320,017), lipids that reduce the aggregation of lipid particles 4 such as monosialogangliosides, etc., relative low toxicity lipids for adjusting toxicity, lipids having functional groups that bind ligands to lipid particles 4, sterols, such as cholesterol, etc., for inhibiting the leakage of encapsulated materials, etc.

[0112] Due to the particularly excellent nucleic acid encapsulation amount and nucleic acid delivery efficiency, the lipid particle 4 preferably contains, for example, a compound represented by formula (1-01) or formula (1-02), a compound represented by formula (2-01), DOPE and / or DOTAP, cholesterol and DMG-PEG. For example, it is preferred that these components are included in any of the compositions 1 to 6 listed in Table 1 below.

[0113] Table 1: Composition of lipid particles (molar ratio)

[0114]

[0115] In addition to the donor DNA 2 and RNA agent, the lipid particles 4 can also encapsulate additional compounds. Examples of such compounds include: compounds that regulate the expression of nucleic acids in cells, such as retinoic acid, cyclic adenosine monophosphate (cAMP) or ascorbic acid; peptides, polypeptides, cytokines, growth factors, apoptosis factors, differentiation inducing factors, cell surface receptors and their ligands, anti-inflammatory compounds, antidepressants, stimulants, analgesics, antibiotics, contraceptives, antipyretics, vasodilators, angiogenesis inhibitors, cell vascular agonists, signal transduction inhibitors, cardiovascular drugs, tumor drugs, hormones and steroids, etc.

[0116] The nucleic acid delivery vector 1 can be manufactured by using a known method used, for example, when encapsulating small molecules in lipid particles, including the Bangham method, organic solvent extraction, surfactant removal, freeze-thaw, etc. For example, the nucleic acid introduction vector 1 can be prepared by adding an aqueous buffer containing donor DNA 2 and RNA agent 3 to a mixture obtained by containing the material of the lipid particle 4 in an organic solvent such as alcohol, and stirring and suspending. The volume ratio of the RNA agent 3 encapsulated in the lipid particle 4 and the donor DNA 2 can be easily adjusted by changing the volume ratio between the two in the aqueous buffer.

[0117] The encapsulated amount of DNA and RNA can be determined by using, for example, commercially available DNA and RNA quantification kits.

[0118] The average particle size of the nucleic acid delivery vector 1 is about 50nm to about 300nm, preferably about 50nm to about 200nm. When the nucleic acid delivery vector 1 is used for medical purposes, it is preferred that the nucleic acid delivery vector 1 is a nanometer-level particle. For example, the particle size can be made smaller by ultrasound. In addition, the size can be adjusted by passing the nucleic acid delivery vector 1 through a polycarbonate membrane or a ceramic membrane. The average particle size of the nucleic acid delivery vector 1 can be measured by, for example, a ζ sorter using dynamic light scattering.

[0119]

Nucleic acid delivery method

[0120] The following describes a method for delivering a nucleic acid using the above-mentioned nucleic acid delivery vector. The method for delivering a nucleic acid is a method for integrating the first sequence into the genome of a cell, and comprises contacting the nucleic acid delivery vector with a cell.

[0121] Figure 2 is a schematic flow chart showing an example of a nucleic acid delivery method. For example, the nucleic acid delivery method includes the following steps:

[0122] (S1) contacting the nucleic acid delivery vector with cells;

[0123] (S2) expressing a protein in the cell from the RNA contained in the RNA agent by contacting; and

[0124] (S3) Integrating the first sequence into the cell genome by using the activity of the protein.

[0125] In the nucleic acid delivery method, the practitioner of the method performs step (S1), and steps (S2) and (S3) occur spontaneously due to the activity of the molecules contained in the nucleic acid delivery vector and the intrinsic mechanism originally existing in the cell.

[0126] The cell may be derived from a human, an animal or a plant, or may be derived from a microorganism such as a bacterium or a fungus. The cell is preferably an animal cell, more preferably a mammalian cell, most preferably a human cell. The cell is preferably a blood and immune cell, a mesenchymal cell, an epithelial cell, an endothelial cell or a tissue stem cell or a pluripotent stem cell.

[0127] The cell can be, for example, a cell collected ex vivo, and can be, for example, a cell separated from a body fluid (such as blood), a tissue, or a biopsy. The cell can be, for example, an isolated cell or a cell line. Alternatively, the cell can be an in vivo cell. The expressions "a cell", "the cell" and "cells" can include one cell (single) and multiple cells (several, cell groups, cell clusters or cell clusters).

[0128] When the cells are cells or microorganisms collected in vitro, the step of contacting the nucleic acid delivery vector 1 with the cells 7 may include, for example, adding a composition containing the nucleic acid delivery vector 1 to the cells or microorganisms for culturing. For example, it is preferred that the cells are cultured for 30 to 48 hours under conditions suitable for cell survival after addition.

[0129] If the cell is an in vivo cell of an animal, contact is performed by in vivo administration of a composition containing the nucleic acid delivery vector 1. Administration can be performed, for example, by parenteral routes, such as subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intramedullary, intraocular, intrahepatic, intralesional, and intracranial injection or drip.

[0130] If the cells are plant cells, the composition containing the nucleic acid delivery vector 1 can be administered by immersing the plant in the composition or injecting the composition into the plant using a syringe or the like.

[0131] The enzyme used in the nucleic acid delivery method of the present embodiment is not limited to CAS9 and transposase, and the first sequence 5 can be introduced by using enzymes involved in other nucleic acid transfer at the same time.

[0132] According to the nucleic acid delivery method of this embodiment, the enzyme can be introduced in the form of RNA. Therefore, compared with the case of delivery in the form of DNA, the transcription step can be omitted, so that the enzyme can be expressed faster and more effectively. Therefore, the first sequence 5 can be more effectively integrated.

[0133] In addition, if the enzyme is introduced in the form of a protein, it is necessary to adjust the size and composition of the lipid particles 4 according to the size and characteristics of the encapsulated protein. In contrast, if the RNA form is used in the nucleic acid delivery method of the present embodiment, the composition of the lipid particles 4 is relatively unrestricted. Therefore, compared with the case of delivery in the form of a protein, the time and cost for manufacturing the nucleic acid delivery vector can be reduced.

[0134] In addition, when the enzyme in the form of DNA is introduced, the enzyme gene can be integrated into the cell genome, which may cause adverse effects in the cell or the organism containing the cell. In contrast, according to the nucleic acid delivery method of the present embodiment, the enzyme is introduced in the form of RNA. Therefore, the enzyme is not integrated into the cell genome, so adverse effects can be prevented.

[0135] In addition, when nucleic acid is introduced into cells by binding to lipids such as liposomes, there is a possibility that the nucleic acid is degraded or aggregated with unwanted molecules. Moreover, it is difficult to adjust the abundance ratio of the nucleic acid to be introduced. In contrast, according to the method of the present embodiment, donor DNA 2 and RNA agent 3 are encapsulated in the cavity 4b of lipid particle 4. Therefore, donor DNA 2 and RNA agent 3 can be protected from degradation or aggregation. In addition, the volume ratio between donor DNA 2 and RNA agent 3 to be introduced can be easily adjusted. Therefore, donor DNA 2 and RNA agent 3 can be effectively introduced into cells, RNA can be expressed, and then the first sequence 5 can be integrated.

[0136] The delivery efficiency can be further increased by using nucleic acid condensing peptides 6 , by causing RNA degradation, and / or by including biodegradable lipid compounds in the lipid particles 4 .

[0137] This nucleic acid delivery method is suitable for DNA transfection such as genome editing or gene recombination. For example, when the first sequence 5 comprises a gene expression cassette and a gene or a portion of a gene, the gene can be integrated into the cell genome by the above-mentioned nucleic acid delivery method. Therefore, the cell can obtain a new function mediated by the gene. Alternatively, the normal function of the gene can be given to, for example, a gene-deficient cell, a defective cell, a gene-deficient cell, or a partially defective cell.

[0138] Alternatively, the first sequence 5 can be integrated to knock out a gene on the cell genome. For example, a gene expressing a product that is harmful to the cell or an overexpressed gene can be knocked out to make the cell function normally. In addition, a gene knockout (KO) model organism can be created.

[0139] The nucleic acid delivery method is applicable to, but not limited to, various fields, such as gene therapy, model animal production, gene function analysis, drug development, gene drive and / or transgenic crop production. The method of this embodiment enables the target gene to be more effectively integrated, thereby increasing the efficacy of gene therapy, the efficiency of model animal production, the effect of gene function analysis, the efficiency of drug development, the effect or efficiency of gene drive, or the effect or efficiency of the production of transgenic organisms.

[0140]

Composition

[0141] One embodiment provides a composition including the nucleic acid delivery vector 1 and a vector.

[0142] Examples of carriers include water, saline (eg, physiological saline), aqueous glycine solutions or buffered solutions.

[0143] In addition to the nucleic acid delivery vector and the medium, the composition of the present embodiment may include additional components. Examples of additional components include, but are not limited to, for example, glycoproteins such as albumin, lipoprotein, apolipoprotein, globulin, etc., agents for improving stability; in the case of medical use, such as pH adjusters, buffering agents, tonicity adjusters, etc., for example, pharmaceutically acceptable agents such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc., and related agents that make the pharmaceutical composition close to the physiological state; lipid protective agents such as lipid-affinity free radical quenchers such as α-growth phenol that inhibit damage caused by free radicals, or water-soluble chelating agents such as ferrioxamine that inhibit peroxidative damage to lipids, etc. for improving storage stability. After forming the nucleic acid delivery vector, it is preferred to add the medium and additional components.

[0144] The composition may be, for example, a pharmaceutical composition comprising components that can be administered pharmaceutically. In addition, the composition of the embodiment may be sterilized by conventional well-known methods.

[0145] The composition may be provided as a liquid, or may be provided as a dry powder. A powdered composition may be used, for example, by dissolving it in a suitable liquid.

[0146] The concentration of the nucleic acid delivery vector contained in the composition of the present embodiment is not limited, but is preferably 0.01 to 30% by mass, more preferably 0.05 to 10% by mass. The concentration is appropriately selected depending on the intended purpose.

[0147]

Reagent test kit

[0148] One embodiment provides a kit including a nucleic acid delivery vector. This kit, for example, includes the above-mentioned composition, which includes a nucleic acid delivery vector and a reagent for delivering the nucleic acid delivery vector to a cell. Alternatively, a kit is provided in which a dispersion of the material of the lipid particle 4 is dispersed in a medium and a donor DNA 2 and an RNA agent 3 are contained in a separate container, or a kit in which dried lipid particles 4, donor DNA 2, and RNA agent 3 and a medium are contained in a separate container, etc. Furthermore, dried lipid particles 4 or a dispersion of the material of lipid particles 4 and donor DNA 2 and RNA agent 3 can also be used as separate products, and the user can select the form of each product according to the purpose.

[0149] In another container, the kit may include additional chemical reagents that may be included in the above-described compositions.

[0150] (Second embodiment)

[0151] The second embodiment provides a nucleic acid delivery vector in which the donor DNA 2 and the RNA agent 3 have a core-shell structure. Figure 3 This is a cross-sectional view showing the nucleic acid delivery carrier according to the second embodiment.

[0152] Figure 3 The nucleic acid delivery carrier 100 shown in (a) has a core-shell structure including a donor DNA core 15 containing a donor DNA 2 and an RNA agent shell 16 containing an RNA agent 3 coating the donor DNA core 15. The core-shell structure is encapsulated in a lipid particle 4.

[0153] For example, the nucleic acid delivery vector 100 can be manufactured as follows. First, the donor DNA 2 is condensed using a nucleic acid condensing peptide to produce a donor DNA core 15. Next, by contacting the RNA agent 3 with the donor DNA core 15, the RNA contained in the RNA agent 3 is electrostatically attached to the surrounding of the donor DNA core 15 to form an RNA agent shell 16. The RNA agent 3 can be condensed in advance with a nucleic acid condensing peptide. This results in the formation of a core-shell structure. Subsequently, the core-shell structure is added to a solvent containing a material of the lipid particle 4. Then, the mixture is stirred, thereby encapsulating the core-shell structure in the lipid particle 4. In this way, the nucleic acid delivery vector 100 can be produced.

[0154] This structure allows sequential delivery of donor DNA 2 and RNA agent 3. For example, when the nucleic acid delivery vector 100 is introduced into a cell, RNA agent 3 as a shell is released faster than donor DNA 2 as a core. Then, the enzyme produced from the RNA contained in the RNA agent 3 reaches the nucleus faster than the donor DNA 2. Thus, once the donor DNA 2 reaches the nucleus, the first sequence 5 integration begins, so that the integration efficiency can be improved.

[0155] Figure 3 The nucleic acid delivery carrier 101 shown in (b) has a core-shell structure including an RNA agent core 17 containing an RNA agent 3 and a donor DNA shell 18 containing a donor DNA 2 coating the RNA agent core 17. The core-shell structure is enclosed in a lipid particle 4.

[0156] For the nucleic acid delivery vector 101, for example, the RNA agent 3 is condensed using a nucleic acid condensing peptide to produce an RNA agent core 17, and the donor DNA 2 is brought into contact with the core. In this way, a donor DNA shell 18 is formed. The donor DNA 2 may be condensed with a nucleic acid condensing peptide in advance. Subsequently, the resulting core-shell structure is added to a solvent containing a material of the lipid particle 4. Then, the mixture may be stirred to produce the nucleic acid delivery vector 101.

[0157] Due to such a structure, for example, when the nucleic acid delivery vector 101 is introduced into a cell, the donor DNA 2 as a shell is released faster than the RNA agent 3, and the RNA agent 3 undergoes sustained release. Due to this, even if the enzyme produced from the RNA agent is degraded in the cell, the enzyme can be provided because the RNA is released again from the RNA agent core 17. Therefore, the first sequence 5 integration effect can be sustained for a long period of time.

[0158] The configuration of the nucleic acid delivery vector can be selected according to the cell type used. For example, in cells with slow protein degradation, even if the enzyme produced from the RNA agent is translocated to the nucleus, in cells without problems, it can be used Figure 3 (a) to improve the integration efficiency. Alternatively, for example, in cells that are easily degraded or consumed by enzymes, such as cells with a fast cell cycle or cells that degrade proteins quickly, the use of Figure 3 The nucleic acid introduction vector 101 shown in (b) can improve the integration efficiency.

[0159] The release rate and duration of the nucleic acid contained in the core can be adjusted by the composition or amount of the nucleic acid condensing peptide or the amount of the nucleic acid.

[0160] Similar to the nucleic acid delivery vector of the first embodiment, the nucleic acid delivery vector 100 or 101 can be used for a nucleic acid delivery method. In addition, each vector can be provided as a kit or composition similar to the first embodiment.

[0161] (Third embodiment)

[0162] The third embodiment provides a nucleic acid delivery vector set including individual lipid particles 4 , each of which encapsulates a donor DNA 2 or an RNA agent 3 . Figure 4 is an example of a nucleic acid delivery vector set. The nucleic acid delivery vector set 200 includes a first vector 201 and a second vector 202. The first vector 201 includes a donor DNA 2 and a first lipid particle 41 encapsulating the donor DNA 2. The second vector 202 includes an RNA agent 3 and a second lipid particle 42 encapsulating the RNA agent 3. The donor DNA 2 or the RNA agent 3 is each encapsulated in a state of being condensed using a nucleic acid condensing peptide.

[0163] The first carrier 201 and the second carrier 202 can be produced separately. For example, the first carrier 201 and the second carrier 202 can be obtained by condensing the donor DNA 2 and the RNA agent 3 with nucleic acid condensing peptides, respectively, and mixing and stirring the solutions with the lipid particle-containing materials.

[0164] The nucleic acid delivery vector set 200 can be provided as a composition or a kit similar to that of Embodiment 1. For example, the first vector 201 and the second vector 202 are provided as a composition contained in separate containers or a composition contained in the same container.

[0165] The nucleic acid delivery vector set 200 is applicable to a nucleic acid delivery method similar to the nucleic acid delivery vector of Embodiment 1. According to the nucleic acid delivery vector set 200, in the nucleic acid delivery method, either the first vector 201 or the second vector 202 can be brought into contact with cells first.

[0166] For example, when using the above cells, it is preferred that the vector 3 of the RNA agent 3 is first transferred to the nucleus, and the second vector 202 is preferably brought into contact with the cells before the first vector 201. For example, it is preferred that the first vector 201 is brought into contact with the second vector 202 30 minutes to 48 hours later.

[0167] Alternatively, as described above, when using cells that preferentially allow donor DNA 2 to migrate into the nucleus first and continuously release RNA agent 3, it is preferred that the first vector 201 be brought into contact with the cells before the second vector 202. For example, it is preferred that the cells be brought into contact with the first vector 201 and then with the second vector 202 30 minutes to 48 hours later.

[0168] Optionally, both may be contacted with the cells simultaneously.

[0169] When the donor DNA 2 and the RNA agent 3 are sequentially introduced by using the nucleic acid delivery vector set 300, the delivery time difference can be easily adjusted. [Example]

[0170] Next, examples of preparation and use of a nucleic acid delivery vector according to an embodiment are described.

[0171] [Example 1: Evaluation of NanoLuc gene introduction efficiency and expression efficiency of DNA encapsulation vector]

[0172] Preparation of DNA encapsulation vector

[0173] As DNA, plasmid DNA was used in which the NanoLuc gene was connected downstream of the cytomegalovirus promoter. To the DNA solution containing the DNA, a cationic peptide was added to form a condensed DNA peptide. Next, it was added to an ethanol-soluble fat solution (FFT10 (a biodegradable lipid compound represented by formula (1-01)) / DOTAP / cholesterol / PEG-DMG=73 / 44 / 59 / 4mol). In addition, 10mM HEPES (pH7.3) was gently added. The mixture was then washed and concentrated by centrifugal ultrafiltration to produce a DNA encapsulation vector. The DNA encapsulation amount of the vector was measured using the Quant-iT (registered trademark) PicoGreen dsDNA assay kit (manufactured by Thermo Fisher Scientific). Then, it was verified that the DNA was sufficiently encapsulated.

[0174] Preparation of Jurkat and nucleic acid delivery using DNA encapsulation vectors

[0175] Human T-cell leukemia cells (Jurkat obtained from ATCC) were cultured in TexMACS medium (manufactured by Miltenyi Biotec K.K.). After the cells were recovered by centrifugation, the cells were suspended in fresh TexMACS to a concentration of 0.65×10 7 Then, 150 μl of cell suspension and TexMACS were added to each well of the 48-well culture plate until the volume reached 1.0×10 6 cells / well.

[0176] Thereafter, the DNA encapsulation vector was added to each well at 0.5 μg of DNA / well, and the mixture was incubated at 37° C. in an atmosphere of 5% CO 2 .

[0177]

Introducing DNA into cells using Lipofectamine 3000

[0178] As a control, the above plasmid DNA was introduced into Jurkat using Lipofectamine 3000 reagent (manufactured by Invitrogen). The introduction was performed according to the instructions attached to the reagent. Plasmid DNA was added to Jurkat to become 0.5 μg / well, and the mixture was cultured at 37°C and 5% CO2 atmosphere.

[0179]

Determination of NanoLuc expression level (NanoLuc luminescence assay)

[0180] 48 hours after the addition of plasmid DNA mixed with DNA encapsulation vector or Lipofectamine 3000, the culture plate was collected from the incubator. Then, the luminescence intensity of NanoLuc was measured using the Nano-Glo luciferase assay system (manufactured by Promega) using a luminometer (Infinite (registered trademark) F200 PRO, manufactured by Tecan). The measurement was performed according to the instructions attached to the kit and the device.

[0181]

Results of NanoLuc luminescence assay

[0182] Figure 5 The results of measuring the luminescence intensity of NanoLuc are shown. The introduction using the DNA encapsulation vector caused a higher luminescence intensity than the introduction using Lipofectamine 3000. This result shows that in the cells into which the DNA was introduced by using the DNA encapsulation vector, the DNA was well introduced and the NanoLuc gene was well expressed. This shows that the method of introducing DNA by vector encapsulation has higher DNA introduction efficiency and gene expression efficiency than the method using a complex of DNA and liposome.

[0183]

Microscope luminescent cell detection

[0184] Next, using cells into which DNA was introduced by a carrier or liposome 3000, luminescent cells were detected by using a luminescent microscope system (LV200, manufactured by Olympus). 24 hours after introduction, 100 μl of cell culture fluid was transferred to a 4-well culture dish and NanoLuc matrix (live cell luciferase assay kit manufactured by Promega) was added. After the culture dish was set at a predetermined position in the luminescent microscope system (LV200 manufactured by Olympus), bright field images and luminescent images of cells were captured.

[0185]

Results of microscopic observation

[0186] Figure 6 Captured images of luminescent cells are shown (images obtained by merging bright field images and luminescent images by Matamorph software). The white dots indicated by arrows in the photographs are luminescent cells. Figure 6 (a) shows a microscope image of cells encapsulated with DNA vectors, and Figure 6 (b) is a microscope image of cells using Liposome 3000. The two were compared. It is obvious that the case of using the DNA encapsulation vector has a much larger number of luminescent cells than the case of using Liposome 3000. This result has demonstrated that, as in the NanoLuc luminescence assay, the case of using the DNA encapsulation vector has higher DNA introduction efficiency and gene expression efficiency than the case of using the complex of liposome and DNA.

[0187] [Example 2: Evaluation of the introduction efficiency and expression efficiency of the green fluorescent protein (GFP) gene by mRNA encapsulation vector]

[0188] Preparation of RNA encapsulation vector

[0189] As messenger RNA (mRNA), mRNA of green fluorescent protein (GFP) as a reporter gene (manufactured by OZ Biosciences) was used. The RNA solution containing the mRNA was added to an ethanol-soluble fat solution (FFT10 / DOPE / cholesterol / PEG-DMG=73 / 44 / 59 / 4mol), and the mixture was suspended by a pipette. Then, 10mM HEPES (pH 7.3) was gently added. The solution was washed and concentrated with centrifugal ultrafiltration to produce an RNA encapsulation vector. The RNA encapsulation amount of the vector was measured with the QuantiFluor (registered trademark) RNA system (manufactured by Promega), and the mRNA was verified to be encapsulated in sufficient amount.

[0190] Preparation and use of RNA-encapsulated vectors to introduce nucleic acids into Jurkat

[0191] Jurkat cells were cultured in TexMACS medium. After the cells were collected by centrifugation, they were suspended in fresh TexMACS medium to a concentration of 0.65 × 10 7 Then, 150 μl of cell suspension and TexMACS were added to each well of the 48-well culture plate until the volume reached 1.0×10 6 cells / well.

[0192] Thereafter, the RNA encapsulation vector was added to the wells to give 0.5 μg / well of mRNA, and the mixture was incubated at 37° C. in an atmosphere of 5% CO 2 .

[0193]

Introducing mRNA into cells using Lipofectamine 3000

[0194] As a control, the above mRNA was introduced into Jurkat using Lipofectamine 3000 reagent. The introduction was carried out according to the instructions attached to the reagent. mRNA was added to the wells to a concentration of 0.5 μg / well, and the mixture was incubated at 37°C in an atmosphere of 5% CO2.

[0195]

Detection of GFP expression

[0196] 24 hours after adding mRNA mixed with RNA encapsulation vector or Liposome 3000, the culture plate was collected from the incubator. After recovery by centrifugation, the cells were suspended in phosphate buffered saline (PBS) containing 1% BSA (manufactured by Gibco, Thermo Fisher Scientific). Then, the green fluorescence of GFP was detected using a fluorescence activated cell sorter (FACS; FACSVerse (registered trademark), manufactured by BD Bioscience).

[0197]

result

[0198] Figure 7 The detection results are displayed. Figure 7 (a) shows the results using RNA encapsulation vectors, Figure 7 (b) shows the results of using Lipofectamine 3000. Each figure shows a histogram in which the ordinate represents the cell count (%) and the abscissa represents the GFP expression intensity. Each solid line histogram shows the distribution of cells into which RNA was introduced, and each dotted line histogram shows the distribution of cells into which RNA was not introduced (control).

[0199] like Figure 7 As shown in the figure (a), when the RNA encapsulation vector is introduced, the distribution of the fluorescence intensity of the cells is significantly shifted to the right compared to the control, indicating that GFP is well expressed in the cells. This reveals that GFP mRNA is well introduced and GFP is well expressed.

[0200] In contrast, Figure 7 As shown in (b), in the case where RNA was introduced using a liposome reagent, the distribution of fluorescence intensity was almost the same as that of the control, indicating that the introduction or expression of GFP mRNA was weak.

[0201] Therefore, this indicates that the method of introducing mRNA by using vector encapsulation has higher mRNA introduction efficiency and gene expression efficiency than the method using a complex of mRNA and liposome.

[0202] [Example 3: Evaluation of the introduction efficiency and expression efficiency of the GFP gene introduced in the form of mRNA (RNA encapsulation vector) and in the form of DNA (DNA encapsulation vector)]

[0203] Preparation of RNA encapsulation vector

[0204] As mRNA, the GFP mRNA described in Example 2 was used. An RNA solution containing GFP mRNA was added to an ethanol-soluble fat solution (FFT10 / DOPE / cholesterol / PEG-DMG=73 / 44 / 59 / 4 mol), and the mixture was suspended by pipetting. Then, 10 mM HEPES (pH 7.3) was gently added. The solution was washed and concentrated by centrifugal ultrafiltration to produce an RNA encapsulation vector. The RNA encapsulation amount of the vector was measured using the QuantiFluor (registered trademark) RNA system to verify that the mRNA was encapsulated in sufficient amount.

[0205] Preparation of DNA encapsulation vector

[0206] As DNA, plasmid DNA is used, wherein the GFP gene is connected to the cytomegalovirus promoter downstream. Next, a cationic peptide is added to the DNA solution containing the DNA to condense the DNA. Then, it is added to an ethanol-soluble fat solution (FFT10 / DOTAP / cholesterol / PEG-DMG=73 / 44 / 59 / 4mol). Then, 10mM HEPES (pH7.3) is added gently. The mixture is then washed and concentrated by centrifugal ultrafiltration to produce a DNA encapsulation vector. The DNA encapsulation amount of the vector is measured with Quant-iT (registered trademark) PicoGreen dsDNA assay kit (manufactured by Thermo Fisher Scientific). Then, it was verified that the DNA was encapsulated in sufficient amounts.

[0207] Preparation and use of Jurkat vectors to introduce nucleic acids

[0208] Jurkat cells were cultured in TexMACS medium. After the cells were collected by centrifugation, they were suspended in fresh TexMACS medium to a concentration of 0.65 × 10 7 Then, 150 μl of cell suspension and TexMACS were added to each well of the 48-well culture plate until the volume reached 1.0×10 6 cells / well.

[0209] RNA encapsulated vectors or DNA encapsulated vectors were added to each well of a separate well culture plate. Each plate was incubated at 37°C and in an atmosphere of 5% CO2.

[0210]

Detection of GFP expression

[0211] 24 hours after the addition of the vector, each culture plate was taken out from the incubator. After recovery by centrifugation, the cells were suspended in a phosphate buffered saline (PBS) containing 1% BSA (manufactured by Gibco, Thermo Fisher Scientific). Then, the green fluorescence (GFP) of the cells was detected by FACS.

[0212]

result

[0213] Figure 8 The detection results are displayed. Figure 8 (a) shows the results using RNA encapsulation vectors, Figure 8 (b) shows the results of using DNA encapsulation vectors. Each figure shows a histogram in which the ordinate represents cell count (%) and the abscissa represents GFP expression intensity. Each solid line histogram shows the distribution of cells into which RNA or DNA was introduced using the corresponding vector, and each dotted line histogram shows the distribution of cells into which RNA or DNA was not introduced.

[0214] like Figure 8 As shown in (a), when the GFP gene was introduced in the form of mRNA, the distribution of fluorescence intensity shifted significantly to the right compared to the control, indicating that GFP was well expressed by the cells. This revealed that GFP mRNA was well introduced and GFP was well expressed.

[0215] On the contrary, Figure 8 As shown in (b), the fluorescence intensity distribution in the case where the GFP gene was introduced in the form of DNA was almost the same as that of the control, indicating that DNA introduction or GFP expression was weak.

[0216] In general, it has been demonstrated that the introduction of GFP in the form of mRNA results in higher nucleic acid introduction efficiency and gene expression efficiency than the case of introduction in the form of DNA.

[0217] [Example 4: Evaluation of the introduction efficiency and expression efficiency of the GFP gene using a DNA / RNA co-encapsulation vector]

[0218]

Preparation of RNA / DNA co-encapsulation vector and its introduction into Jurkat

[0219] A mixed solution containing the plasmid DNA containing the NanoLuc gene described in Example 1 and the mRNA encoded by the GFP gene described in Example 2 was added to an ethanol-soluble fat solution (FFT10 / DOPE / cholesterol / PEG-DMG=73 / 44 / 59 / 4mol). In addition, 10mM HEPES (pH7.3) was gently added. The mixture was then washed and concentrated by centrifugal ultrafiltration to produce an RNA / DNA encapsulated vector. The RNA encapsulation amount of the vector was measured using the QuantiFluor (registered trademark) RNA system, and the DNA encapsulation amount was measured using the Quant-IT (registered trademark) PicoGreen dsDNA assay kit. Then, it was verified that the mRNA and DNA were encapsulated in sufficient amounts.

[0220] Jurkat cells were cultured in TexMACS medium. After the cells were collected by centrifugation, they were suspended in fresh TexMACS medium to a concentration of 0.65 × 10 7 Then, 150 μl of cell suspension and TexMACS were added to each well of the 48-well culture plate until the volume reached 1.0×10 6 Thereafter, the DNA / RNA encapsulation vector was added to each well to give 0.5 μg of mRNA and 0.5 μg of DNA per well, and the mixture was incubated at 37° C. in an atmosphere of 5% CO 2 .

[0221]

Introducing mRNA and DNA into cells using Lipofectamine 3000

[0222] As a control, mRNA and plasmid DNA were introduced into Jurkat using Lipofectamine 3000 reagent. The introduction was performed according to the instructions attached to the reagent. mRNA and plasmid DNA were added to Jurkat to a concentration of 0.5 μg / well, and the mixture was incubated at 37°C in an atmosphere of 5% CO2.

[0223]

NanoLuc and GFP expression detection

[0224] The expression of NanoLuc from NanoLuc DNA was detected using the Nano-Glo luciferase assay system, and the expression of GFP from GFP mRNA was detected by FACS. Each was detected by the protocol described in Example 1 or 2.

[0225]

result

[0226] Fig. 9 Results of detecting NanoLuc expression are shown. Fig. 9The graph shown reveals that the case of introducing DNA and RNA using a vector causes higher relative luminescence intensity than the case of using Lipofectamine 3000. This result indicates that the case of using a vector has better DNA introduction efficiency and gene expression efficiency from DNA.

[0227] Fig.10 The results of detecting GFP expression are shown. Fig.10 (a) shows the results using vector, Fig.10 (b) shows the results of using Lipofectamine 3000. These histograms reveal that the case of using the vector caused higher GFP fluorescence intensity than the case of using Lipofectamine 3000. This result indicates that the case of using the vector has better mRNA introduction efficiency and gene expression efficiency from mRNA.

[0228] The above results indicate that the DNA / RNA co-encapsulation vector can increase the introduction efficiency and expression efficiency of DNA and RNA by simultaneous introduction.

[0229] [Example 5: Evaluation of DNA and RNA Sequential Introduction into DNA Encapsulation Vectors and RNA Encapsulation Vectors]

[0230] Preparation of DNA encapsulation vector

[0231] As DNA, plasmid DNA in which the NanoLuc gene expression cassette linking the cytomegalovirus promoter and the NanoLuc gene was integrated was used. The DNA encapsulation vector was prepared by the method described in Example 1.

[0232] Preparation of RNA encapsulation vector

[0233] As RNA, transposase RNA was used. The RNA encapsulation vector was prepared by the protocol described in Example 2.

[0234]

Cell preparation and use of vectors to introduce nucleic acids

[0235] Commercially available frozen human peripheral blood mononuclear cells (PBMC, LONZA) were thawed at 37°C in a constant temperature incubator and recovered by centrifugation. The cells were suspended in TexMACS containing 2 different cytokines (10ng / ml IL-7 and 5ng / ml IL-15 (Miltenyi)) and then seeded on a 6cm culture dish. The cells were then cultured in an incubator at 37°C and 5% CO2. After overnight culture, the culture dish was removed from the incubator. The cells were recovered by centrifugation and suspended in TexMACS (containing 10ng / ml IL-7 and 5ng / ml IL-15), and then cultured overnight at 37°C and 5% CO2 on a 48-well culture plate coated with anti-CD3 antibody (Miltenyi) and anti-CD28 antibody (Miltenyi).

[0236] The transposase RNA encapsulation vector (4 μg) was added to the cell culture medium, and the mixture was cultured in an atmosphere of 5% CO 2. After 2 hours, the NanoLuc DNA encapsulation vector (4 μg) was further added, and the culture was continued.

[0237] As a control, the transposase RNA encapsulation vector (4 μg) and the NanoLuc DNA encapsulation vector (4 μg) were simultaneously added to the same type of cell culture medium, and the mixture was cultured in an atmosphere of 5% CO 2 .

[0238]

NanoLuc luminescence detection

[0239] 48 hours after the addition of the first vector, each culture plate was removed from the incubator. Then, the luminescence intensity of each NanoLuc was measured using a luminometer (Infinite (registered trademark) F200 PRO, manufactured by Tecan) using the Nano-Glo luciferase assay system (manufactured by Promega). Each luminescence was measured according to the instructions attached to the kit and the device.

[0240]

result

[0241] Fig.11 The results of measuring the luminescence intensity of NanoLuc are shown. After 2 hours of adding the RNA encapsulation vector, a higher luminescence intensity of NanoLuc was detected in the case of adding the DNA encapsulation vector compared to the case of adding the DNA encapsulation vector and the RNA encapsulation vector at the same time. This result shows that the sequential introduction of the transposase mRNA that assists the introduction of DNA and the DNA containing the sequence to be integrated effectively increases the protein expression level from the DNA. In addition, it has been demonstrated that the method of this embodiment makes it possible to effectively introduce (transfect) and express DNA in PBMCs that are generally considered to have low nucleic acid introduction efficiency.

[0242] [Example 6: Evaluation of nucleic acid introduction efficiency using a vector having a DNA / RNA core-shell structure]

[0243]

Preparation of DNA / RNA core / shell encapsulated vector

[0244] As DNA, plasmid DNA was used, in which a CAR gene expression cassette connecting a cytomegalovirus promoter and a CAR gene was integrated; and as RNA, the GFP mRNA described in Example 2 was used. A cationic peptide was added to a DNA solution containing the DNA to form a DNA core. Then, the above-mentioned RNA was added to form an RNA shell around the DNA core. As a result, a solution containing a DNA / RNA core / shell was prepared. Next, it was added to an ethanol-soluble fat solution (FFT10 / DOTAP / cholesterol / PEG-DMG=73 / 44 / 59 / 4mol). In addition, 10mM HEPES (pH 7.3) was gently added. The mixture was then washed and concentrated by centrifugal ultrafiltration to produce a carrier with a DNA / RNA core / shell structure.

[0245]

Preparation of DNA / RNA mixed encapsulation vector

[0246] As a control, a cationic peptide was added to a mixed solution containing the above DNA and RNA to prepare a solution containing a DNA / RNA mixed core. This was added to an ethanol-soluble fat solution (FFT10 / DOTAP / cholesterol / PEG-DMG=73 / 44 / 59 / 4 mol). In addition, 10 mM HEPES (pH 7.3) was gently added. The mixture was then washed and concentrated by centrifugal ultrafiltration to produce a DNA / RNA mixed encapsulation vector.

[0247] Confirmation of DNA / RNA encapsulation in vectors

[0248] Next, to examine whether DNA and RNA were encapsulated in the resulting vectors, each vector was disrupted (by adding a surfactant: sodium dodecyl sulfate) and each core structure was disintegrated (by adding polyglutamic acid). Then, each released DNA / RNA was detected by agarose electrophoresis.

[0249] Fig.12 The detection results are shown. In the DNA / RNA core / shell encapsulation vector and the DNA / RNA mixed core encapsulation vector, when the vector destruction and the core structure disintegration are both performed once, the DNA and RNA signals (arrows in the image) are detected. This result shows that the DNA / RNA core / shell encapsulation vector and the DNA / RNA mixed core encapsulation vector contain DNA and RNA aggregates.

[0250]

Fluorescence microscopy observation of cells

[0251] After introduction into Jurkat using the DNA / RNA core / shell encapsulation vector or the DNA / RNA hybrid core encapsulation vector, green fluorescent cells (GFP-expressing cells) were detected under a fluorescence microscope. Fig.13 Microscope photographs showing the results are shown. In the case of DNA / RNA hybrid core encapsulation vectors, at the 20-hour time point ( Fig.13 (b) No GFP-expressing cells were detected. However, GFP-expressing cells were detected after 4 days ( Fig.13 (d)). In contrast, in the case of DNA / RNA core / shell encapsulated vectors, the number of Fig.13 (a)) GFP expressing cells were detected. These results indicate that the expression of RNA in DNA / RNA core / shell is faster than that in DNA / RNA mixed core. In summary, it has been demonstrated that in the case of DNA / RNA core / shell encapsulation vectors, the DNA / RNA core disintegrates sequentially within the cell, and the corresponding proteins can be expressed sequentially from shell RNA to core DNA.

[0252] Although certain embodiments have been described, these embodiments are presented only by way of example and are not intended to limit the scope of the invention. In fact, the novel embodiments described herein may be implemented in a variety of other forms; in addition, various omissions, substitutions, and changes in the form of the embodiments described herein may be made without departing from the spirit of the invention. The accompanying claims and their equivalents are intended to cover forms or modifications that would fall within the scope and spirit of the invention.

Claims

1. A nucleic acid delivery vector for integrating a first sequence into a cell genome, the nucleic acid delivery vector comprising: a donor DNA comprising the first sequence; An RNA agent comprising at least an RNA encoding a protein involved in integrating the first sequence into the genome; and a lipid particle encapsulating the donor DNA and the RNA agent, The lipid particles comprise a compound represented by the following formula (1-01) or the following formula (1-02):

2. The nucleic acid delivery vector according to claim 1, wherein the donor DNA and the RNA agent have a core-shell structure, wherein the donor DNA is the core and the RNA agent is the shell.

3. The nucleic acid delivery vector according to claim 1, wherein the donor DNA and the RNA agent have a core-shell structure, wherein the RNA agent is the core and the donor DNA is the shell. 4 . The nucleic acid delivery vector according to claim 1 , wherein the protein is an enzyme having endonuclease activity.

5. The nucleic acid delivery vector of claim 4, wherein the protein is CRISPR associated protein 9 (CAS9).

6. The nucleic acid delivery vector of claim 5, wherein the RNA agent further comprises a guide RNA comprising a sequence corresponding to a sequence on the genome into which the first sequence is integrated.

7. The nucleic acid delivery vector according to any one of claims 1 to 3, wherein the protein is a transposase.

8. The nucleic acid delivery vector of claim 7, wherein the protein is PiggyBac, SleepingBeauty, Frog Prince, Hsma, Minos, Tol1, Tol2, Passport, hAT, Ac / Ds, PIF, Harbinger, Harbinger3-DR, Himar1, Hermes, Tc3, or Mos1.

9. The nucleic acid delivery vector according to any one of claims 1 to 8, wherein the RNA agent further comprises RNA encoding a DNA methylation protein, RNA encoding a DNA demethylation protein, RNA encoding a DNA repair protein, and / or RNA encoding a DNA binding protein. 10 . The nucleic acid delivery vector according to claim 1 , wherein the RNA contained in the RNA agent is modified to be resistant to degradation.

11. The nucleic acid delivery vector according to any one of claims 1 to 10, wherein the donor DNA and / or RNA agent is condensed using a nucleic acid condensing peptide.

12. The nucleic acid delivery vector according to any one of claims 1 to 11, wherein the lipid particle further comprises a biodegradable lipid represented by the following formula: P-[XWY-W'-Z]2 in P is an alkyleneoxy group containing at least one ether bond in the main chain, X is each independently a divalent linking group containing a tertiary amine structure, W is each independently a C1-C6 alkylene group, Y is each independently a divalent linking group selected from a single bond, an ether bond, a carboxylate bond, a thiocarboxylate bond, a thioester bond, an amide bond, a urethane bond, and a urea bond, W' is each independently a single bond or a C1-C6 alkylene group, Z's are each independently a fat-soluble vitamin residue, a sterol residue or a C12-C22 aliphatic hydrocarbon group.

13. A nucleic acid delivery vector set for integrating a first sequence into a cell genome, the nucleic acid delivery vector set comprising: A first vector comprising: a donor DNA comprising the first sequence, and a first lipid particle encapsulating the donor DNA; and A second vector comprising: an RNA agent comprising at least an RNA encoding a protein involved in integrating the first sequence into the genome, and a second lipid particle encapsulating the RNA agent, The lipid particles comprise a compound represented by the following formula (1-01) or the following formula (1-02):

14. A nucleic acid delivery composition comprising: The nucleic acid delivery vector according to any one of claims 1 to 12 or the nucleic acid delivery vector set according to claim 13; and medium.

15. A nucleic acid delivery method, which uses a nucleic acid delivery vector to integrate a first sequence into a cell genome, Wherein the nucleic acid delivery vector comprises: a donor DNA comprising the first sequence; An RNA agent comprising at least an RNA encoding a protein involved in integrating the first sequence into the genome; and a lipid particle encapsulating the donor DNA and the RNA agent, The lipid particles comprise a compound represented by the following formula (1-01) or the following formula (1-02): And wherein the method comprises: The nucleic acid delivery vehicle is contacted with the cell.

16. The method according to claim 15, further comprising: contacting the nucleic acid delivery vector with the cell to express a protein from the RNA in the cell; and The first sequence is integrated into the cell genome by using the activity of the protein.

17. The method according to claim 15 or 16, wherein the donor DNA and the RNA agent in the nucleic acid delivery vector have a core-shell structure, wherein the donor DNA is the core and the RNA agent is the shell.

18. The method of claim 17, wherein the protein expressed from the RNA reaches the nucleus of the cell faster than the donor DNA.

19. The method according to claim 15 or 16, wherein the donor DNA and the RNA agent in the nucleic acid delivery vector have a core-shell structure, wherein the RNA agent is the core and the donor DNA is the shell.

20. The method of claim 19, wherein the RNA agent undergoes sustained release in the cell.

21. A nucleic acid delivery method, which uses a nucleic acid delivery vector set to integrate a first sequence into a cell genome, The nucleic acid delivery vector set comprises: A first vector comprising: a donor DNA comprising the first sequence, and a first lipid particle encapsulating the donor DNA; and A second vector comprising: an RNA agent comprising at least an RNA encoding a protein involved in integrating the first sequence into the genome, and a second lipid particle encapsulating the RNA agent, The lipid particles comprise a compound represented by the following formula (1-01) or the following formula (1-02): And wherein the method comprises: The first vector and the second vector are contacted with the cell.

22. The method of claim 21, wherein the second vector is contacted with the cell after the first vector is contacted with the cell.

23. The method of claim 21, wherein the first vector is contacted with the cell after the second vector is contacted with the cell.

24. The method of claim 21, wherein the first vector and the second vector are contacted with the cell simultaneously.

25. The method according to any one of claims 15 to 24, wherein the protein is an enzyme having endonuclease activity.

26. The method of claim 25, wherein the protein is CRISPR associated protein 9 (CAS9).

27. The method of claim 26, wherein the RNA agent further comprises a guide RNA comprising a sequence corresponding to a sequence on the genome into which the first sequence is integrated.

28. The method according to any one of claims 15 to 24, wherein the protein is a transposase.

29. The method of claim 28, wherein the protein is PiggyBac, SleepingBeauty, FrogPrince, Hsma, Minos, Tol1, Tol2, Passport, hAT, Ac / Ds, PIF, Harbinger, Harbinger3-DR, Himar1, Hermes, Tc3, or Mos1.